Large Iranian Study Proves The Potential Of Polypill Concept

Data presented in The Lancet medical journal suggests a polypill fixed-dose combination of aspirin, atorvastatin and hydrochlorothiazide with either enalapril or valsartan could reduce the risk of cardiovascular events significantly. 

Iran_Map
Research conducted in the Golestan province of Iran supports the use of a polypill to reduce cardiovascular risk • Source: Shutterstock

A large-scale study in which more than 3,000 Iranians took ‘polypill’ tablets combining the blood-thinner aspirin, the cholesterol-lowering agent atorvastatin and the diuretic hydrochlorothiazide with either the enalapril or valsartan antihypertensives found that “use of a polypill was effective in preventing major cardiovascular events.”

Presenting their findings in TheLancet medical journal, researchers from the Tehran University of Medical Sciences and the University of Birmingham...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Value Added Medicines

  • Neuraxpharm Enters Japanese Market 1

     
    • By 

    Neuraxpharm has expanded its footprint outside of Europe with the launch of its first product in Japan, in the form of the Buccolam value-added midazolam product gained through a deal with Takeda.

  • Hyloris Sets Out Plans To Expand Its Pipeline

     
    • By 

    After partnering with companies like Purna Female Healthcare and AFT Pharmaceuticals, Belgian value-added medicines specialist Hyloris has announced plans to add three new products to its pipeline in the coming months with a goal of having 14 commercial products by 2024. 

  • Awards Offers Two Weeks Of Online Networking

     
    • By 

    From 20 October, a free online platform will allow registrants attending the digital Global Generics & Biosimilars Awards 2020 to participate in two weeks of dedicated networking activities ahead of the ceremony on 3 November.

  • Hyloris And Purna Strike Value-Added Development Deal

     
    • By 

    Value-added medicines specialist Hyloris has struck a deal worth up to €4.3m with Purna Female Healthcare to develop a treatment for vulvovaginal candidiasis that combines miconazole and domiphen bromide.

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.